As of close of business last night, Travere Therapeutics Inc’s stock clocked out at $7.31, down -5.19% from its previous closing price of $7.71. In other words, the price has decreased by -$0.40 from its previous closing price. On the day, 1069182 shares were traded.
Ratios:
To gain a deeper understanding of TVTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.47. In the meantime, Its Debt-to-Equity ratio is 2.02 whereas as Long-Term Debt/Eq ratio is at 1.99.
On December 05, 2023, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $7 to $10.
On November 20, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $7.Citigroup initiated its Neutral rating on November 20, 2023, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 01 ’24 when Dube Eric M sold 19,122 shares for $8.70 per share. The transaction valued at 166,435 led to the insider holds 350,600 shares of the business.
REED ELIZABETH E sold 4,764 shares of TVTX for $41,495 on Feb 01 ’24. The SVP, GC & CORPORATE SECRETARY now owns 76,270 shares after completing the transaction at $8.71 per share. On Feb 01 ’24, another insider, ROTE WILLIAM E., who serves as the SENIOR VICE PRESIDENT, R&D of the company, sold 4,764 shares for $8.71 each. As a result, the insider received 41,495 and left with 80,720 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 557.50M and an Enterprise Value of 395.43M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.80 while its Price-to-Book (P/B) ratio in mrq is 2.74. Its current Enterprise Value per Revenue stands at 2.72 whereas that against EBITDA is -1.21.
Stock Price History:
Over the past 52 weeks, TVTX has reached a high of $23.17, while it has fallen to a 52-week low of $5.25. The 50-Day Moving Average of the stock is 8.19, while the 200-Day Moving Average is calculated to be 10.06.
Shares Statistics:
It appears that TVTX traded 1.23M shares on average per day over the past three months and 965.17k shares per day over the past ten days. A total of 75.37M shares are outstanding, with a floating share count of 75.03M. Insiders hold about 1.41% of the company’s shares, while institutions hold 113.69% stake in the company. Shares short for TVTX as of Mar 15, 2024 were 10.07M with a Short Ratio of 8.16, compared to 9.76M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 13.24% and a Short% of Float of 13.30%.
Earnings Estimates
As of right now, 11 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.97 for the current quarter, with a high estimate of -$0.55 and a low estimate of -$1.27, while EPS last year was -$1.27. The consensus estimate for the next quarter is -$0.82, with high estimates of -$0.63 and low estimates of -$1.08.
Analysts are recommending an EPS of between -$2.43 and -$4.1 for the fiscal current year, implying an average EPS of -$3.18. EPS for the following year is -$1.75, with 11 analysts recommending between $0.16 and -$2.46.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $44.37M. It ranges from a high estimate of $60.85M to a low estimate of $38M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $56.99M, an estimated decrease of -22.10% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $51.75M, a decrease of -13.30% over than the figure of -$22.10% in the same quarter last year. There is a high estimate of $66M for the next quarter, whereas the lowest estimate is $42M.
A total of 14 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $267M, while the lowest revenue estimate was $174M, resulting in an average revenue estimate of $216.11M. In the same quarter a year ago, actual revenue was $145.24M, up 48.80% from the average estimate. Based on 15 analysts’ estimates, the company’s revenue will be $309.08M in the next fiscal year. The high estimate is $513.31M and the low estimate is $218M. The average revenue growth estimate for next year is up 43.00% from the average revenue estimate for this year.
